(A) Percentage of patients with haemoglobin >12g/dl and >13g/dl from all patients that started PEG-EPO after being treated with other non-PEGylated ESA. (B) Percentage of patients with haemoglobin >13g/dl as compared to all patients with haemoglobin >12g/dl in the group of patients that started treatment with PEG-EPO after having received treatment with non-PEGylated ESA. ESA: erythropoiesis-stimulating agents; Hb: haemoglobin; PEG-EPO: methoxy polyethylene glycol-epoetin beta.